ANN ARBOR, Mich., Jan. 29 /PRNewswire/ -- Rubicon Genomics, Inc., a developer of pre-analytical amplification products that enable more comprehensive genetic analysis of clinical and research samples, announced today that it has reached agreement with ZyGEM to non-exclusively market Rubicon’s PicoPlex(TM) single-cell amplification kits in Australia and New Zealand.
“Since its introduction in July of 2009, interest in PicoPlex kits in the research and commercial markets has been strong. The PicoPlex technology nicely complements ZyGEM’s advanced DNA extraction products and we are looking forward to bringing this cutting-edge technology to the markets we serve in Australia and New Zealand,” said Paul Kinnon, CEO of ZyGEM.
PicoPlex has become the leading method for amplifying single cells for pre-implantation genetic diagnostics and screening (PGD/PGS) of human embryos, and it is expected to displace current technologies for amplifying genomic DNA from circulating tumor cells, tumor tissue, stem cells and forensic samples. The PicoPlex technology is one of a series of new amplification technologies being introduced into the nucleic acid testing market by Rubicon Genomics.
About Rubicon Genomics
Rubicon is a pre-analytical platform company that commercializes reagents and kits to increase the analytical and clinical performance of instrument platforms including qPCR, microarrays, and next-generation sequencing. Rubicon kits amplify small clinical samples into large amounts of pure DNA with uniform concentration and molecular weight that increase the sensitivity, specificity, and reproducibility of analysis in research and diagnostic applications, including single cells, formalin-fixed tissue and plasma. Rubicon sells licenses and kits to the clinical markets, including pre-implantation and prenatal testing, cancer testing, and diagnostic manufacturing. For more information and to contact Rubicon, visit www.rubicongenomics.com.
CONTACT: Jim Koziarz, President & CEO of Rubicon Genomics,
+1-847-780-4410, jkoziarz@midwestvp.com; or Paul Kinnon, President & CEO of
ZyGEM, +1-858-720-8333; or Media: Barbara Lindheim of BioCom Partners,
+1-212-918-4650, for Rubicon Genomics, Inc.
Web site: http://www.rubicongenomics.com/
http://www.zygem.com/
